author-photo

Gary M. Clark

University of Texas Health Science Center at San Antonio
Baylor College of Medicine
OSI Pharmaceuticals

215

Papers

44652

Citations

Citation Trend

Filter By

Papers (215) Sort By

Journal Conference Others

A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Redefining adequate margins in oral squamous cell carcinoma: outcomes from close and positive margins

2020 European Archives of Oto-rhino-laryngology
Show All
- Source
- Cite
- Save
Citations (4)
Impact of race and tumor subtype on second malignancy risk in women with breast cancer

2016 SpringerPlus
Show All
- Source
- Cite
- Save
Citations (7)
Analysis of Factors for Clinical Assessment of Gentamicin Resistance

2016
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P1-09-02: Higher incidence of second cancers in African American (AA) patients compared to Caucasian patients with a primary breast cancer:

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

2008 Molecular Oncology
- Gary M. Clark
Show All
- Source
- Cite
- Save
Citations (105)
Transitions across the school years

2008
Show All
- Source
- Cite
- Save
Citations (0)
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

2007 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3257)
Reporting recommendations for tumor marker prognostic studies (remark).

2006 Experimental Oncology
Show All
- Source
- Cite
- Save
Citations (73)
Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib

2006 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (77)